Cargando…

Biomarkers in asthma: state of the art

Asthma is a heterogenous disease characterized by multiple phenotypes driven by different mechanisms. The implementation of precision medicine in the management of asthma requires the identification of phenotype-specific markers measurable in biological fluids. To become useful, these biomarkers nee...

Descripción completa

Detalles Bibliográficos
Autor principal: Tiotiu, Angelica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302401/
https://www.ncbi.nlm.nih.gov/pubmed/30598830
http://dx.doi.org/10.1186/s40733-018-0047-4
_version_ 1783381970421547008
author Tiotiu, Angelica
author_facet Tiotiu, Angelica
author_sort Tiotiu, Angelica
collection PubMed
description Asthma is a heterogenous disease characterized by multiple phenotypes driven by different mechanisms. The implementation of precision medicine in the management of asthma requires the identification of phenotype-specific markers measurable in biological fluids. To become useful, these biomarkers need to be quantifiable by reliable systems, reproducible in the clinical setting, easy to obtain and cost-effective. Using biomarkers to predict asthma outcomes and therapeutic response to targeted therapies has a great clinical significance, particularly in severe asthma. In the last years, significant research has been realized in the identification of valid biomarkers for asthma. This review focuses on the existent and emerging biomarkers with clinical higher applicability in the management of asthma.
format Online
Article
Text
id pubmed-6302401
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63024012018-12-31 Biomarkers in asthma: state of the art Tiotiu, Angelica Asthma Res Pract Review Asthma is a heterogenous disease characterized by multiple phenotypes driven by different mechanisms. The implementation of precision medicine in the management of asthma requires the identification of phenotype-specific markers measurable in biological fluids. To become useful, these biomarkers need to be quantifiable by reliable systems, reproducible in the clinical setting, easy to obtain and cost-effective. Using biomarkers to predict asthma outcomes and therapeutic response to targeted therapies has a great clinical significance, particularly in severe asthma. In the last years, significant research has been realized in the identification of valid biomarkers for asthma. This review focuses on the existent and emerging biomarkers with clinical higher applicability in the management of asthma. BioMed Central 2018-12-21 /pmc/articles/PMC6302401/ /pubmed/30598830 http://dx.doi.org/10.1186/s40733-018-0047-4 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Tiotiu, Angelica
Biomarkers in asthma: state of the art
title Biomarkers in asthma: state of the art
title_full Biomarkers in asthma: state of the art
title_fullStr Biomarkers in asthma: state of the art
title_full_unstemmed Biomarkers in asthma: state of the art
title_short Biomarkers in asthma: state of the art
title_sort biomarkers in asthma: state of the art
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302401/
https://www.ncbi.nlm.nih.gov/pubmed/30598830
http://dx.doi.org/10.1186/s40733-018-0047-4
work_keys_str_mv AT tiotiuangelica biomarkersinasthmastateoftheart